Cigna Group
For the period ended Sep 30, 2025. Filed Oct 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Earnings Per Share
Note 6 – Earnings Per Share
Basic and diluted earnings per share were computed as follows:
| Three Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| September 30, 2025 · September 30, 2024 | |||||||||||
| (Shares in thousands, dollars in millions, except per share amounts) · Basic · Effect ofDilution · Diluted · Basic · Effect ofDilution · Diluted | |||||||||||
| Shareholders' net income | $1,868 | $1,868 | $739 | $739 | |||||||
| Shares: | |||||||||||
| Weighted average | 265,913 | 265,913 | 278,457 | 278,457 | |||||||
| Common stock equivalents | 1,617 | 1,617 | 2,939 | 2,939 | |||||||
| Total shares | 265,913 | 1,617 | 267,530 | 278,457 | 2,939 | 281,396 | |||||
| Earnings per share | $7.02 | $(0.04) | $6.98 | $2.65 | $(0.02) | $2.63 | |||||
| Nine Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| September 30, 2025 · September 30, 2024 | |||||||||||
| (Shares in thousands, dollars in millions, except per share amounts) · Basic · Effect ofDilution · Diluted · Basic · Effect ofDilution · Diluted | |||||||||||
| Shareholders' net income | $4,723 | $4,723 | $2,010 | $2,010 | |||||||
| Shares: | |||||||||||
| Weighted average | 267,635 | 267,635 | 282,005 | 282,005 | |||||||
| Common stock equivalents | 1,892 | 1,892 | 3,037 | 3,037 | |||||||
| Total shares | 267,635 | 1,892 | 269,527 | 282,005 | 3,037 | 285,042 | |||||
| Earnings per share | $17.65 | $(0.13) | $17.52 | $7.13 | $(0.08) | $7.05 | |||||
The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| (In millions) | 2025 | 2024 | 2025 | 2024 |
| Anti-dilutive options | 2.1 | 0.8 | 1.9 | 1.0 |
The Company held approximately 137.4 million shares of common stock in treasury as of September 30, 2025,128.7 million shares as of December 31, 2024 and 122.5 million shares as of September 30, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.